- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Enerion is a synthetic compound similar in structure to thiamine, in comparison with which the molecule has an open thiazole cycle, an additional disulfide bond, a lipophilic ether. Thanks to this modification, sulbutiamine is highly soluble in fats, is rapidly absorbed from the gastrointestinal tract and easily penetrates the BBB; unlike thiamine, it can accumulate in cells of the reticular formation, hippocampus and dentate gyrus, as well as Purkinje cells and glomeruli of the granular layer of the cerebellar cortex. Against the background of Enerion's intake, coordination of movement is improved and resistance to physical exertion increases, the stability of the cerebral cortex structures to repetitive anoxia increases. The drug is effective in the symptomatic treatment of functional asthenia.
Sulbutiamine quickly absorbed, Cmax drug in blood plasma is achieved within 1-2 hours after administration. T1/2 - about 5 hours. The drug is excreted in the urine.
Symptomatic treatment of functional asthenia.
1 coated tablet contains:
active substance: sulbutiamine 200 mg,
Excipients: corn starch - 12 mg; dried starch paste - 40 mg; glucose (dextrose) anhydrous - 20 mg; lactose monohydrate - 65.5 mg; magnesium stearate - 3.5 mg; Talc - 9 mg,
shell: sodium bicarbonate - 0,603 mg; sodium carboxymethylcellulose - 0.556 mg; white beeswax - 0,201 mg; titanium dioxide (E171) - 8.43 mg; ethyl cellulose - 0.485 mg; “Sunset” yellow (Sunset yellow FCF, E110) - 3 mg; glycerol monooleate - 0,242 mg; Polysorbate 80 - 0.302 mg; Povidone - 0.692 mg; sucrose - 106.956 mg; silicon dioxide colloidal anhydrous (Aerosil 130) - 0.404 mg, talc - 28.21 mg
No customer reviews for the moment.
Dosage and Administration
For oral use. Enerion is recommended for use only in adult patients.
Daily dose - 2-3 pills (400-600 mg) in 2 doses (during breakfast and lunch). The duration of treatment should not exceed 4 weeks.
Allergic reactions (the presence of Sunset dye yellow in the formulation), digestive disorders, neuropsychiatric reactions (tremor, headache, agitation, general malaise).
Hypersensitivity to any of the components of the drug Enerion.
Carefully: persons under 18 years of age (it is not recommended to prescribe the drug due to the lack of clinical data).
Pregnancy and Lactation
According to the results of clinical studies, Enerion does not affect the development of the fetus. However, due to the lack of sufficient clinical data, Enerion is not recommended for use during pregnancy, as well as during breastfeeding, since It is currently unknown if sulbutiamine is able to pass into breast milk.
The composition of the excipients of the drug Enerion includes lactose monohydrate. As a consequence, this drug is not recommended for people with lactose deficiency, galactosemia or glucose / galactose malabsorption syndrome.
Influence on the ability to drive and perform work requiring high speed psychomotor reactions. Does not affect.
Symptoms: excitement with symptoms of euphoria and tremor of the extremities are transient in nature and do not require special treatment.
- Brand name: Enerion
- Active ingredient: Sulbutiamine
- Dosage form: Coated pills
- Manufacturer: Servier
- Country of Origin: France
- Potentiometric sensors for the selective determination of sulbutiamine
- Sulbutiamine in sports
- Determination of sulbutiamine and its disulfide derivatives in human plasma by HPLC using on-line post-column reactors and fluorimetric detection
- Chronic administration of sulbutiamine improves long term memory formation in mice: Possible cholinergic mediation
- Injection of sulbutiamine induces an increase in thiamine triphosphate in rat tissues
- Chronic treatment with sulbutiamine improves memory in an object recognition task and reduces some amnesic effects of dizocilpine in a spatial delayed-non-match-to-sample task
- Effets de l’association de la Sulbutiamine à un inhibiteur de l’acétylcholinestérase dans les formes légères à modérées de la maladie d’Alzheimer
- Traitement de l'asthénie en période postinfectieuse: étude randomisée en double aveugle de deux doses de sulbutiamine (400–600 mg/j) versus placebo
- Evidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain
- Facilitation de l'etat de veille d'un traitement semi-chronique par la Sulbutiamine (Arcalion) chez Macaca mulatta
- Sulbutiamine, an ‘innocent’ over the counter drug, interferes with therapeutic outcome of bipolar disorder
- Validated HPLC-DAD method for stability study of sulbutiamine HCl
- Sulbutiamine abuse
- Age‐related changes in the hamster's circadian system partially reversed by treatment with Sulbutiamine, a vit b‐1 related compound
- Stability-Indicating HPTLC Method for Studying Stress Degradation Behavior of Sulbutiamine HCl
- Development and Validation of Stability Indicating Spectrophotometric Methods for Determination of Sulbutiamine in Tablet Dosage Form
- Development of a novel method for the bioanalysis of benfotiamine and sulbutiamine in cancer cells
- Evidence for Neuroprotective Effect of Sulbutiamine against Oxygen–Glucose Deprivation in Rat Hippocampal CA1 Pyramidal Neurons
- Kinetic Spectrophotometric Determination of Sulbutiamine in Pharmaceutical Preparations and in Human Serum.
- Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis